These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1178 related articles for article (PubMed ID: 30558987)

  • 1. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
    Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
    Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Sportelli P; Miskin HP; Weiss MS; O'Brien S
    Blood; 2019 Nov; 134(21):1811-1820. PubMed ID: 31558467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
    Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
    Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Lee CS; Rattu MA; Kim SS
    J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
    Pagel JM; Soumerai JD; Reddy N; Jagadeesh D; Stathis A; Asch A; Salman H; Kenkre VP; Iasonos A; Llorin-Sangalang J; Li J; Zelenetz AD
    Lancet Oncol; 2022 Aug; 23(8):1021-1030. PubMed ID: 35835137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
    O'Brien S; Furman RR; Coutre SE; Sharman JP; Burger JA; Blum KA; Grant B; Richards DA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Izumi R; Hamdy A; Chang BY; Graef T; Clow F; Buggy JJ; James DF; Byrd JC
    Lancet Oncol; 2014 Jan; 15(1):48-58. PubMed ID: 24332241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
    Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
    Brown JR; Hamadani M; Hayslip J; Janssens A; Wagner-Johnston N; Ottmann O; Arnason J; Tilly H; Millenson M; Offner F; Gabrail NY; Ganguly S; Ailawadhi S; Kasar S; Kater AP; Doorduijn JK; Gao L; Lager JJ; Wu B; Egile C; Kersten MJ
    Lancet Haematol; 2018 Apr; 5(4):e170-e180. PubMed ID: 29550382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
    Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.